Finance
Finance
āĻšā§‹āĻŽHPX â€ĸ FRA
Hisamitsu Pharmaceutical Co Inc
ā§Šā§§.ā§Žā§Ļâ‚Ŧ
⧍ āĻāĻĒā§āϰāĻŋ, ā§§ā§Ļ:ā§Ģā§Ŧ:⧍ā§Ē PM GMT +⧍ · EUR · FRA · āĻĄāĻŋāϏāĻ•ā§āϞ⧇āĻŽāĻžāϰ
āĻ¸ā§āϟāĻ•DE-āĻ āϤāĻžāϞāĻŋāĻ•āĻžāϭ⧁āĻ•ā§āϤ āϏāĻŋāĻ•āĻŋāωāϰāĻŋāϟāĻŋJP-āĻ āĻšā§‡āĻĄāĻ•ā§‹ā§ŸāĻžāĻ°ā§āϟāĻžāϰ
āĻ•āĻžāϞ āĻļ⧇āώ āϝ⧇ āĻĻāĻžāĻŽā§‡ āĻ›āĻŋāϞ
ā§Šā§¨.ā§Ļā§Ļâ‚Ŧ
āϏāĻžāϰāĻž āĻĻāĻŋāύ⧇āϰ āĻŸā§āϰ⧇āĻĄāĻŋāĻ‚ā§Ÿā§‡ āĻ¸ā§āϟāϕ⧇āϰ āĻĻāĻžāĻŽā§‡āϰ āĻ“āĻ āĻž āύāĻžāĻŽāĻžāϰ āϰ⧇āĻžā§āϜ
ā§Šā§§.ā§Žā§Ļâ‚Ŧ - ā§Šā§§.ā§Žā§Ļâ‚Ŧ
āϏāĻžāϰāĻž āĻŦāĻ›āϰ⧇āϰ āϰ⧇āĻžā§āϜ
⧍⧧.ā§Ēā§Ļâ‚Ŧ - ā§Šā§Ģ.ā§Ŧā§Ļâ‚Ŧ
āĻŽāĻžāĻ°ā§āϕ⧇āϟ āĻ•ā§āϝāĻžāĻĒ
ā§Ē.ā§Ģā§Ēāϕ⧋ JPY
P/E āĻ…āύ⧁āĻĒāĻžāϤ
-
āϞāĻ­ā§āϝāĻžāĻ‚āĻļ āĻĒā§āϰāĻĻāĻžāύ
-
āĻĒā§āϰāĻžāχāĻŽāĻžāϰāĻŋ āĻāĻ•ā§āϏāĻšā§‡āĻžā§āϜ
TYO
āĻŦāĻžāϜāĻžāϰ āϏāĻ‚āĻŦāĻžāĻĻ
AMD
ā§Š.ā§Ēā§­%
.INX
ā§Ļ.ā§§ā§§%
āĻĢāĻžāχāύāĻžāĻ¨ā§āϏāĻŋ⧟āĻžāϞ āĻĒāĻžāϰāĻĢāĻ°ā§āĻŽā§āϝāĻžāĻ¨ā§āϏ
āĻ†ā§Ÿā§‡āϰ āĻ¸ā§āĻŸā§‡āϟāĻŽā§‡āĻ¨ā§āϟ
āωāĻĒāĻžāĻ°ā§āϜāύ
āύ⧇āϟ āχāύāĻ•āĻžāĻŽ
(JPY)āύāϭ⧇ ⧍ā§Ļ⧍ā§ĢY/Y āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
āωāĻĒāĻžāĻ°ā§āϜāύ
ā§Š.⧝ā§ŦāĻļāĻ¤Â āϕ⧋⧧ā§Ļ.ā§Ģā§Ē%
āĻŦā§āϝāĻŦāϏāĻž āϚāĻžāϞāĻžāύ⧋āϰ āĻ–āϰāϚ
ā§§.ā§Žā§­āĻļāĻ¤Â āϕ⧋ā§Ģ.ā§Ļā§Ģ%
āύ⧇āϟ āχāύāĻ•āĻžāĻŽ
ā§Ēā§Žā§Ŧ.ā§Žā§Ļ āϕ⧋ā§Ŧ.ā§­ā§§%
āύ⧇āϟ āĻĒā§āϰāĻĢāĻŋāϟ āĻŽāĻžāĻ°ā§āϜāĻŋāύ
——
āĻļā§‡ā§ŸāĻžāϰ āĻĒā§āϰāϤāĻŋ āωāĻĒāĻžāĻ°ā§āϜāύ
——
EBITDA
ā§Ŧā§Ļā§Ŧ.ā§Ēā§ŽÂ āĻ•ā§‹â€”
āĻĒā§āϰāϝ⧋āĻœā§āϝ āĻŸā§āϝāĻžāĻ•ā§āϏ⧇āϰ āĻšāĻžāϰ
——
āĻŽā§‹āϟ āϏāĻŽā§āĻĒāĻĻ
āĻŽā§‹āϟ āĻĻāĻžā§Ÿ
(JPY)āύāϭ⧇ ⧍ā§Ļ⧍ā§ĢY/Y āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
āĻ•ā§āϝāĻžāĻļ āĻ“ āĻ•āĻŽ āϏāĻŽā§Ÿā§‡āϰ āĻŦāĻŋāύāĻŋā§Ÿā§‹āĻ—
ā§§.ā§§ā§§āϕ⧋-ā§Ģ.ā§Ļā§Š%
āĻŽā§‹āϟ āϏāĻŽā§āĻĒāĻĻ
ā§Š.ā§Ē⧍āϕ⧋⧍.⧍ā§Ē%
āĻŽā§‹āϟ āĻĻāĻžā§Ÿ
ā§­.ā§Ļā§­āĻļāĻ¤Â āϕ⧋-⧍.ā§Ģā§Ļ%
āĻŽā§‹āϟ āχāϕ⧁āχāϟāĻŋ
⧍.⧭⧍āĻ•ā§‹â€”
āφāωāϟāĻ¸ā§āĻŸā§āϝāĻžāĻ¨ā§āĻĄāĻŋāĻ‚ āĻļā§‡ā§ŸāĻžāϰ
ā§­.ā§Ļā§§Â āĻ•ā§‹â€”
āĻĒā§āϰāĻžāχāϏ āϟ⧁ āĻŦ⧁āĻ• āϰ⧇āĻļāĻŋāĻ“
ā§Ļ.ā§Ļā§§â€”
āϏāĻŽā§āĻĒāĻĻ āĻĨ⧇āϕ⧇ āĻ†ā§Ÿ
——
āĻŽā§‚āϞāϧāύ āĻĨ⧇āϕ⧇ āĻ†ā§Ÿ
——
āύāĻ—āĻĻ⧇ āĻŽā§‹āϟ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
(JPY)āύāϭ⧇ ⧍ā§Ļ⧍ā§ĢY/Y āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
āύ⧇āϟ āχāύāĻ•āĻžāĻŽ
ā§Ēā§Žā§Ŧ.ā§Žā§Ļ āϕ⧋ā§Ŧ.ā§­ā§§%
āĻ…āĻĒāĻžāϰ⧇āĻļāύ āĻĨ⧇āϕ⧇ āĻĒāĻžāĻ“ā§ŸāĻž āĻ•ā§āϝāĻžāĻļ
——
āĻŦāĻŋāύāĻŋā§Ÿā§‹āĻ— āĻĨ⧇āϕ⧇ āĻĒā§āϰāĻžāĻĒā§āϤ āĻ•ā§āϝāĻžāĻļ
——
āĻĢāĻžāχāĻ¨ā§āϝāĻžāĻ¨ā§āϏāĻŋāĻ‚ āĻĨ⧇āϕ⧇ āĻĒā§āϰāĻžāĻĒā§āϤ āĻ•ā§āϝāĻžāĻļ
——
āύāĻ—āĻĻ⧇ āĻŽā§‹āϟ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
——
āĻĢā§āϰāĻŋ āĻ•ā§āϝāĻžāĻļ āĻĢā§āϞ⧋
——
āϏāĻŽā§āĻĒāĻ°ā§āϕ⧇
The Hisamitsu Pharmaceutical Co., Inc., headquartered in Tosu and Tokyo, is a Japanese multinational pharmaceutical corporation that develops and markets prescription and over-the-counter drug products, especially external pain relieving products such as the transdermal patch. Hisamitsu has specialised in transdermal drug delivery system technology since the introduction of its original line of patches in 1903. Hisamitsu's products under the Salonpas and Bye-Bye Fever brands are exported to over fifty countries. Hisamitsu also manufactures the Mohrus and Mohrus-Tape lines of external pain relief prescription products for the Japanese drug market. The company also manufactures internal medicines, eyedrops for general application, and the Lifecella Face Mask, a skincare product. Hisamitsu has developed the only over-the-counter transdermal patches approved by the U.S Food and Drug Administration. Wikipedia
āĻ¸ā§āĻĨāĻžāĻĒāĻŋāϤ āĻšā§Ÿā§‡āϛ⧇
ā§§ā§Žā§Ēā§­
āĻ“ā§Ÿā§‡āĻŦāϏāĻžāχāϟ
āĻ•āĻ°ā§āĻŽāϚāĻžāϰ⧀
⧍,⧭⧝⧝
āφāϰāĻ“ āĻĻ⧇āϖ⧁āύ
āφāĻĒāύāĻžāϰ āĻšā§ŸāϤ āĻĒāĻ›āĻ¨ā§āĻĻ āĻšāĻŦ⧇
āϏāĻŽā§āĻĒā§āϰāϤāĻŋ āĻ•āϰāĻž āϏāĻžāĻ°ā§āϚ, āĻĢāϞ⧋ āĻ•āϰāĻž āϏāĻŋāĻ•āĻŋāωāϰāĻŋāϟāĻŋ āĻāĻŦāĻ‚ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ…ā§āϝāĻžāĻ•ā§āϟāĻŋāĻ­āĻŋāϟāĻŋ āĻĨ⧇āϕ⧇ āĻāχ āϤāĻžāϞāĻŋāĻ•āĻžāϟāĻŋ āĻœā§‡āύāĻžāϰ⧇āϟ āĻ•āϰāĻž āĻšā§Ÿā§‡āϛ⧇āĨ¤ āφāϰāĻ“ āϜāĻžāύ⧁āύ

āϏāĻŽāĻ¸ā§āϤ āĻĄā§‡āϟāĻž āĻ“ āϤāĻĨā§āϝ "āϝ⧇āĻŽāύāĻ­āĻžāĻŦ⧇ āĻĒāĻžāĻ“ā§ŸāĻž āϗ⧇āϛ⧇, āĻ āĻŋāĻ• āϤ⧇āĻŽāύāĻ­āĻžāĻŦ⧇" āĻļ⧁āϧ⧁āĻŽāĻžāĻ¤ā§āϰ āĻŦā§āϝāĻ•ā§āϤāĻŋāĻ—āϤ āϤāĻĨā§āϝ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ⧇ āĻĒā§āϰāĻĻāĻžāύ āĻ•āϰāĻž āĻšā§Ÿā§‡āϛ⧇ āĻāĻŦāĻ‚ āĻļā§‡ā§ŸāĻžāϰ āĻŸā§āϰ⧇āĻĄāĻŋāĻ‚ āĻŦāĻž āĻĢāĻžāχāĻ¨ā§āϝāĻžāĻ¨ā§āϏāĻŋ⧟āĻžāϞ, āĻŦāĻŋāύāĻŋā§Ÿā§‹āĻ—, āĻŸā§āϝāĻžāĻ•ā§āϏ, āφāχāύāĻŋ āĻŦāĻŋāώ⧟, āĻ…ā§āϝāĻžāĻ•āĻžāωāĻ¨ā§āϟāĻŋāĻ‚ āĻŦāĻž āĻ…āĻ¨ā§āϝ āϕ⧋āύāĻ“ āĻĒāϰāĻžāĻŽāĻ°ā§āĻļ āĻŦāĻž āωāĻĒāĻĻ⧇āĻļ āĻĻ⧇āĻ“ā§ŸāĻžāϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ⧇ āϤāĻž āĻ•āϰāĻž āĻšā§ŸāύāĻŋāĨ¤ Google āϕ⧋āύāĻ“ āĻŦāĻŋāύāĻŋā§Ÿā§‹āĻ— āϏāĻ‚āĻ•ā§āϰāĻžāĻ¨ā§āϤ āĻŦāĻž āĻĢāĻžāχāĻ¨ā§āϝāĻžāĻ¨ā§āϏāĻŋ⧟āĻžāϞ āωāĻĒāĻĻ⧇āĻˇā§āϟāĻž āύ⧟ āĻāĻŦāĻ‚ āĻāχ āϤāĻžāϞāĻŋāĻ•āĻžāϤ⧇ āĻ…āĻ¨ā§āϤāĻ°ā§āϭ⧁āĻ•ā§āϤ āϕ⧋āĻŽā§āĻĒāĻžāύāĻŋ āĻ…āĻĨāĻŦāĻž āϏ⧇āχāϏāĻŦ āϕ⧋āĻŽā§āĻĒāĻžāύāĻŋāϰ āχāĻ¸ā§āϝ⧁ āĻ•āϰāĻž āϏāĻŋāĻ•āĻŋāωāϰāĻŋāϟāĻŋāϰ āĻŦā§āϝāĻžāĻĒāĻžāϰ⧇ āϕ⧋āύāĻ“ āϰāĻ•āĻŽ āĻŽāϤāĻžāĻŽāϤ āĻŦā§āϝāĻ•ā§āϤ āĻ•āϰ⧇ āύāĻžāĨ¤ āϝ⧇āϕ⧋āύāĻ“ āϧāϰāύ⧇āϰ āĻŸā§āϰ⧇āĻĄ āĻ•āϰāĻžāϰ āφāϗ⧇, āĻŽā§‚āĻ˛ā§āϝ āϝāĻžāϚāĻžāχ āĻ•āϰ⧇ āύ⧇āĻ“ā§ŸāĻžāϰ āϜāĻ¨ā§āϝ āφāĻĒāύāĻžāϰ āĻŦā§āϰ⧋āĻ•āĻžāϰ āĻŦāĻž āĻĢāĻžāχāĻ¨ā§āϝāĻžāĻ¨ā§āϏāĻŋ⧟āĻžāϞ āĻĒā§āϰāϤāĻŋāύāĻŋāϧāĻŋāϰ āϏāĻžāĻĨ⧇ āφāϞ⧋āϚāύāĻž āĻ•āϰ⧇ āύāĻŋāύāĨ¤ āφāϰāĻ“ āϜāĻžāύ⧁āύ
āϞ⧋āĻ•āϜāύ āĻāϗ⧁āϞāĻŋāĻ“ āĻ–ā§‹āρāĻœā§‡āύ
āϏāĻžāĻ°ā§āϚ āĻ•āϰ⧁āύ
āϏāĻžāĻ°ā§āϚ āĻŽā§āϛ⧁āύ
āϏāĻžāĻ°ā§āϚ āĻŦāĻ¨ā§āϧ āĻ•āϰ⧁āύ
Google āĻ…ā§āϝāĻžāĻĒā§āϞāĻŋāϕ⧇āĻļāĻžāύāϗ⧁āϞāĻŋ
āĻĒā§āϰāϧāĻžāύ āĻŽā§‡āύ⧁